CY1115124T1 - Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης - Google Patents

Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης

Info

Publication number
CY1115124T1
CY1115124T1 CY20141100234T CY141100234T CY1115124T1 CY 1115124 T1 CY1115124 T1 CY 1115124T1 CY 20141100234 T CY20141100234 T CY 20141100234T CY 141100234 T CY141100234 T CY 141100234T CY 1115124 T1 CY1115124 T1 CY 1115124T1
Authority
CY
Cyprus
Prior art keywords
cyanoquinolines
suspensions
substituted
tyrosine kinases
protein tyrosine
Prior art date
Application number
CY20141100234T
Other languages
Greek (el)
English (en)
Inventor
Allan Wissner
Hwei-Ru Tsou
Dan Maarten Berger
Middleton Brawner Floyd Jr
Philip Ross Hamann
Nan Zhang
Philip Frost
Original Assignee
Wyeth Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22585009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115124(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc
Publication of CY1115124T1 publication Critical patent/CY1115124T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20141100234T 1998-09-29 2014-03-28 Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης CY1115124T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16228998A 1998-09-29 1998-09-29
EP10173332.7A EP2253620B1 (en) 1998-09-29 1999-09-22 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Publications (1)

Publication Number Publication Date
CY1115124T1 true CY1115124T1 (el) 2016-04-13

Family

ID=22585009

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100234T CY1115124T1 (el) 1998-09-29 2014-03-28 Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
CY2014034C CY2014034I1 (el) 1998-09-29 2014-08-14 Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2014034C CY2014034I1 (el) 1998-09-29 2014-08-14 Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης

Country Status (28)

Country Link
EP (4) EP2896612A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4537582B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100736502B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1144786C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR035002A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU6159499A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C048I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR9914164A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2344168C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1115124T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ303681B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2253620T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA004427B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2457396T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0055I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1208456A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU230728B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL142092A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTPA2014028I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92428I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20011574L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ510580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL218769B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2253620E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2253620T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK287767B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000018740A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200102501B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298746A1 (en) * 1999-02-27 2011-03-23 Boehringer Ingelheim Pharma GmbH & Co. KG 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE50111799D1 (de) * 2000-04-08 2007-02-15 Boehringer Ingelheim Pharma Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
EP1337524A1 (en) * 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
HUP0402228A2 (hu) * 2001-11-27 2005-02-28 Wyeth Holdings Corporation EGF-R és HER2 kináz inhibitor hatású szubsztituált 3-cianokinolinok, előállításukra szolgáló eljárás, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10217689A1 (de) * 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
DE60318089T2 (de) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004069827A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab Quinoline derivatives and use thereof as antitumor agents
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
UA80607C2 (en) * 2003-04-09 2007-10-10 White Holdings Corp Process for the preparation of 3-cyano-6-alkoxy-7-nitro-4-quinolines
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
RU2378268C2 (ru) 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005070890A2 (en) 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
WO2005096784A2 (en) 2004-04-08 2005-10-20 Targegen, Inc. Benzotriazine inhibitors of kinases
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
EP1756090A1 (en) 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
JP2007537230A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
ES2354457T3 (es) 2005-09-20 2011-03-15 Astrazeneca Ab Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
JP2009533405A (ja) * 2006-04-14 2009-09-17 アストラゼネカ アクチボラグ Ｃｓｆ−１ｒキナーゼ阻害剤としての４−アニリノキノリン−３−カルボキサミド
BRPI0717586A2 (pt) 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN101638383B (zh) * 2008-07-29 2013-07-10 北大方正集团有限公司 喹啉衍生物及其药物组合物和用途
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
HRP20191005T1 (hr) 2009-07-06 2019-08-23 Boehringer Ingelheim International Gmbh Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103748080B (zh) * 2011-05-26 2016-09-28 山东轩竹医药科技有限公司 喹唑啉衍生物类酪氨酸激酶抑制剂及其制备方法与应用
CN202470348U (zh) * 2012-02-29 2012-10-03 珠海格力电器股份有限公司 导风板驱动装置及使用该驱动装置的空调室内机
WO2013131424A1 (zh) * 2012-03-09 2013-09-12 上海恒瑞医药有限公司 4-喹唑啉胺类衍生物及其用途
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
SI3456717T1 (sl) 2015-07-06 2021-08-31 Gilead Sciences, Inc. 4,6-diamino-kinolin-3-karbonitrilni derivat kot modulator cancer osaka thyroid (COT) za zdravljenje vnetne bolezni
JP2021515767A (ja) 2018-03-07 2021-06-24 バイエル・アクチエンゲゼルシヤフト Ｅｒｋ５阻害剤の同定及び使用
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN110540534B (zh) * 2019-10-24 2020-11-13 枣庄学院 一种有机中间体化合物的合成方法
US11655237B2 (en) 2020-03-30 2023-05-23 Gilead Sciences, Inc. Solid forms of a Cot inhibitor compound
WO2021202688A1 (en) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470186A (en) 1967-06-02 1969-09-30 American Cyanamid Co Substituted 4-anilino-3-quinolinecarboxylic acids and esters
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
GB8804443D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
BR9506936A (pt) 1994-02-23 1997-09-09 Pfizer Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
ES2109796T3 (es) 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
PL331154A1 (en) * 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
ATE300521T1 (de) 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives

Also Published As

Publication number Publication date
HUS1700048I1 (hu) 2017-12-28
SK287767B6 (sk) 2011-09-05
PL346972A1 (en) 2002-03-11
EA200100412A1 (ru) 2001-10-22
LTPA2014028I1 (lt) 2014-08-25
BR9914164A (pt) 2001-06-26
JP2002525359A (ja) 2002-08-13
KR100736502B1 (ko) 2007-07-06
EA004427B1 (ru) 2004-04-29
SI2253620T1 (sl) 2014-06-30
PT2253620E (pt) 2014-04-15
NO20011574D0 (no) 2001-03-28
EP1117649A1 (en) 2001-07-25
ZA200102501B (en) 2002-01-05
LU92428I2 (fr) 2014-06-10
CY2014034I2 (el) 2016-04-13
EP2896612A1 (en) 2015-07-22
JP4537582B2 (ja) 2010-09-01
AU6159499A (en) 2000-04-17
BE2014C048I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-03-05
ES2457396T3 (es) 2014-04-25
CZ303681B6 (cs) 2013-03-06
EP2253620A1 (en) 2010-11-24
CY2014034I1 (el) 2016-04-13
IL142092A0 (en) 2002-03-10
HK1208456A1 (en) 2016-03-04
EP2253620B1 (en) 2014-03-12
WO2000018740A1 (en) 2000-04-06
KR20010085856A (ko) 2001-09-07
FR14C0055I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-08-22
CN1320118A (zh) 2001-10-31
NZ510580A (en) 2003-03-28
BRPI9914164B8 (pt) 2021-05-25
SK3892001A3 (en) 2001-12-03
EP1950201A1 (en) 2008-07-30
FR14C0055I2 (fr) 2016-06-10
HUP0103633A2 (hu) 2002-02-28
AR035002A1 (es) 2004-04-14
CZ2001957A3 (cs) 2001-09-12
BRPI9914164B1 (pt) 2019-02-19
CA2344168C (en) 2011-04-05
PL218769B1 (pl) 2015-01-30
HUP0103633A3 (en) 2003-01-28
CA2344168A1 (en) 2000-04-06
CN1144786C (zh) 2004-04-07
IL142092A (en) 2007-07-04
DK2253620T3 (da) 2014-03-31
HU230728B1 (hu) 2017-12-28
NO20011574L (no) 2001-05-28

Similar Documents

Publication Publication Date Title
CY1115124T1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
CY1105618T1 (el) Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
DK1117659T3 (da) Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
IL160915A0 (en) Indolizines inhibiting kinase proteins
EA200400006A1 (ru) Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
WO2000047583A8 (en) Cyclic substituted fused pyrrolocarbazoles and isoindolones
SE0000540D0 (sv) New compounds
CY1107886T1 (el) Αναστολεις κινασης ως θεραπευτικοι παραγοντες
BR9804214A (pt) Compostos.
ATE274348T1 (de) Überbrückte indenopyrrolocarbazole
NO20042534L (no) Forbedringer vedrorende optiske lysgjoringsmidler
EA200301100A1 (ru) Новые фталазиноны
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
UY27606A1 (es) Inhibidores de la fosfarasa
ATE411287T1 (de) Neue metallproteinaseinhibitoren
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate
ATE298236T1 (de) Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose